FIB-4升高与2型糖尿病患者心血管疾病和肝外癌症病史的高发生率相关。
Elevated FIB-4 Is Associated with Higher Rates of Cardiovascular Disease and Extrahepatic Cancer History in Patients with Type 2 Diabetes Mellitus.
作者信息
Karagiannakis Dimitrios S, Stefanaki Katerina, Petrea Foteini, Zacharaki Panagiota, Giannou Alexandra, Michalopoulou Olympia, Kazakou Paraskevi, Psaltopoulou Theodora, Vasileiou Vasiliki, Paschou Stavroula A
机构信息
Academic Department of Gastroenterology, Laiko General Hospital, School of Medicine, National and Kapodistrian University of Athens, 17 Agiou Thoma Street, 11527 Athens, Greece.
Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
出版信息
Biomedicines. 2024 Apr 9;12(4):823. doi: 10.3390/biomedicines12040823.
BACKGROUND
Type 2 diabetes mellitus (T2DM) is often complicated by steatotic liver disease, cardiovascular disease (CVD), and extrahepatic cancer. We investigated whether FIB-4, an indicator of liver fibrosis, is associated with a higher risk of CVD and extrahepatic cancer history in T2DM.
METHODS
Two hundred and nine of 244 diabetics admitted to our center in one year were included and retrospectively evaluated.
RESULTS
One hundred and fifty-two (72.7%) were males and 57 (27.3%) females. The mean age and FIB-4 were 64.3 ± 11 years, and 1.15 ± 0.5, respectively. One hundred and fifty patients (71.8%) had FIB-4 ≤ 1.3, and 59 (28.2%) had FIB-4 > 1.3. A history of CVD was presented in 76 (36.4%) patients, and of extrahepatic cancer in 39 (18.7%). Patients with CVD were significantly older than those without (68.4 ± 8.5 vs. 63.2 ± 11.5 years; = 0.002), with significantly higher FIB-4 (1.26 ± 0.5 vs. 1.08 ± 0.5; = 0.012). Patients with cancer were older, with higher FIB-4 compared to those without (68.2 ± 9.5 vs. 64.4 ± 10.9 years; = 0.098 and 1.37 ± 0.6 vs. 1.1 ± 0.5; = 0.004, respectively). FIB-4 > 1.3 was associated with a 2.1-fold probability for CVD (χ = 5.810; = 0.025) and 2.7-fold probability for cancer history (χ = 7.603; = 0.01).
CONCLUSIONS
FIB-4 ≥ 1.3 is associated with a higher probability of CVD or extrahepatic cancer history. FIB-4 could potentially discriminate patients at risk, justifying stricter surveillance.
背景
2型糖尿病（T2DM）常并发脂肪性肝病、心血管疾病（CVD）和肝外癌症。我们研究了肝纤维化指标FIB-4是否与T2DM患者发生CVD和肝外癌症病史的较高风险相关。
方法
纳入了一年内入住我们中心的244名糖尿病患者中的209名，并进行回顾性评估。
结果
男性152名（72.7%），女性57名（27.3%）。平均年龄和FIB-4分别为64.3±11岁和1.15±0.5。150名患者（71.8%）的FIB-4≤1.3，59名患者（28.2%）的FIB-4>1.3。76名（36.4%）患者有CVD病史，39名（18.7%）有肝外癌症病史。有CVD的患者明显比没有CVD的患者年龄大（68.4±8.5岁对63.2±11.5岁；P=0.002），FIB-4明显更高（1.26±0.5对1.08±0.5；P=0.012）。有癌症的患者年龄更大，与没有癌症的患者相比FIB-4更高（68.2±9.5岁对64.4±10.9岁；P=0.098和1.37±0.6对1.1±0.5；P=0.004）。FIB-4>1.3与发生CVD的概率高2.1倍相关（χ=5.810；P=0.025），与有癌症病史的概率高2.7倍相关（χ=7.603；P=0.01）。
结论
FIB-4≥1.3与发生CVD或肝外癌症病史的概率较高相关。FIB-4可能有助于识别有风险的患者，证明进行更严格的监测是合理的。
Zotero 插件